The recent observation that melanoma cells arrested in the G1 phase have higher sensitivity to MEK inhibitors [29], suggesting a potential benefit of a combination treatment with MEK inhibitors and Rho/MRTF pathway inhibitors. Here, RHO is linked to melanoma.